Several developments from
Zimmer Biomet Holdings (ZBH) have hit the news. There is a focus on the company's recent
earnings results which were disappointing. This sentiment has prompted the action of significant shareholders, as several investment entities, including
Calamos Advisors LLC and
Grandfield & Dodd LLC, have sold large quantities of ZBH shares. Despite this, there are still shareholders like
ABN Amro Investment Solutions and
Illinois Municipal Retirement Fund who acquired and boosted their holdings in ZBH. Amidst this,
legal investigations into potential securities fraud involving the firm have been announced. However, the company made breakthroughs by receiving
FDA approval for their iodine-treated total hip replacement system and their enhanced ROSA® Knee Robotic Technology, which could potentially change ZBH's growth narrative. Also, ZBH unveiled their third quarter financial results of 2025 which indicated strong US growth. Despite recent challenges, ZBH's innovation push and
acquisition of Monogram Technologies creates potential for their long-term value.
Zimmer Biomet Holdings ZBH News Analytics from Mon, 04 Aug 2025 07:00:00 GMT to Sat, 15 Nov 2025 12:52:13 GMT -
Innovation 1
- Information 6
- Rumor 2
